Published in Int J Hypertens on March 28, 2011
The challenge of translating ischemic conditioning from animal models to humans: the role of comorbidities. Dis Model Mech (2014) 0.99
Poor maternal nutrition programmes a pro-atherosclerotic phenotype in ApoE-/- mice. Clin Sci (Lond) (2012) 0.76
Differences in statin usage and target-goal achievement between departments at the same hospital. PLoS One (2012) 0.75
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
A receptor-mediated pathway for cholesterol homeostasis. Science (1986) 19.28
Regulation of the mevalonate pathway. Nature (1990) 18.25
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med (2006) 14.79
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA (2004) 9.91
C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA (2006) 9.27
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA (2001) 9.16
Universal definition of myocardial infarction. Eur Heart J (2007) 9.04
Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem (1996) 8.08
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol (2003) 5.77
Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol (2005) 5.30
Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med (2005) 4.64
The LDL receptor. Arterioscler Thromb Vasc Biol (2009) 3.78
Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation (2004) 3.47
Structural mechanism for statin inhibition of HMG-CoA reductase. Science (2001) 3.45
Protein lipidation in cell signaling. Science (1995) 3.22
The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res (1992) 3.02
Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation (2001) 2.95
Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol (2009) 2.85
Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol (2007) 2.66
Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation (2005) 2.26
Isoprenoids as mediators of the biological effects of statins. J Clin Invest (2002) 2.19
Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol (2009) 2.10
Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol (2006) 1.90
Coronary microembolization: from bedside to bench and back to bedside. Circulation (2009) 1.85
Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol (2005) 1.71
Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J (2004) 1.68
Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol (2001) 1.66
Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv (2010) 1.65
Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). Am J Cardiol (2009) 1.54
HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2003) 1.48
Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab (2002) 1.47
Inflammation imaging in atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.38
Reperfusion injury, microvascular dysfunction, and cardioprotection: the "dark side" of reperfusion. Circulation (2009) 1.37
Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol (2010) 1.33
Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol (2003) 1.33
Statins and cardioprotection--more than just lipid lowering? Pharmacol Ther (2009) 1.27
AMP-activated protein kinase conducts the ischemic stress response orchestra. Circulation (2008) 1.20
Regulation of bone marrow-derived vascular progenitor cell mobilization and maintenance. Arterioscler Thromb Vasc Biol (2010) 1.20
Noninvasive in vivo imaging of monocyte trafficking to atherosclerotic lesions. Circulation (2008) 1.19
Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol (2007) 1.19
Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. J Clin Invest (1987) 1.14
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin (2003) 1.09
The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol (2008) 0.97
Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation (2007) 0.97
Beyond LDL cholesterol, a new role for PCSK9. Arterioscler Thromb Vasc Biol (2010) 0.96
Genetic screening of patients with familial hypercholesterolaemia (FH): a New Zealand perspective. Atheroscler Suppl (2004) 0.96
PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol (2009) 0.95
Usefulness of Nisoldipine for prevention of restenosis after percutaneous transluminal coronary angioplasty (results of the NICOLE study). NIsoldipine in COronary artery disease in LEuven. Am J Cardiol (2001) 0.88
Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc Interv (2004) 0.85
Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem Soc Trans (2003) 0.83
Statin loading for acute coronary syndromes. Curr Opin Cardiol (2010) 0.81
Acute effects of statin therapy on coronary atherosclerosis following an acute coronary syndrome. Am J Cardiol (2009) 0.80
Cell membrane repair as a mechanism for ischemic preconditioning? Circulation (2010) 0.80
Recapturing the magic: revisiting the pleiotropic effects of statins in percutaneous coronary revascularization. J Am Coll Cardiol (2009) 0.78
Effect of hydroxymethylglutaryl coenzyme-a reductase inhibitors on the long-term progression of rheumatic mitral valve disease. Circulation (2010) 0.76
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA (2005) 9.81
Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med (2015) 4.68
Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet (2012) 4.02
Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation (2004) 3.47
Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol (2007) 2.66
Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation. Circulation (2005) 2.49
Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation (2012) 2.44
Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. Am Heart J (2007) 2.38
Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation (2011) 2.34
Carotid artery stenting: first consensus document of the ICCS-SPREAD Joint Committee. Stroke (2006) 2.21
Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation (2007) 2.15
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC Cardiovasc Interv (2013) 2.11
Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery. Ann Thorac Surg (2007) 1.76
Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: a prospective single-center registry in high-risk patients. Catheter Cardiovasc Interv (2008) 1.76
Apoptosis and post-infarction left ventricular remodeling. J Mol Cell Cardiol (2002) 1.63
Results and long-term predictors of adverse clinical events after elective percutaneous interventions on unprotected left main coronary artery. Circulation (2002) 1.62
Impact of bifurcation technique on 2-year clinical outcomes in 773 patients with distal unprotected left main coronary artery stenosis treated with drug-eluting stents. Circ Cardiovasc Interv (2008) 1.60
A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. JACC Cardiovasc Interv (2012) 1.57
High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. J Am Coll Cardiol (2004) 1.52
Incidence, predictors, and outcomes of coronary dissections left untreated after drug-eluting stent implantation. Eur Heart J (2005) 1.51
Contrast agents and renal cell apoptosis. Eur Heart J (2008) 1.49
Rotational atherectomy in resistant chronic total occlusions. Catheter Cardiovasc Interv (2010) 1.47
Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med (2006) 1.46
Effects of atorvastatin on arterial endothelial function in coronary bypass surgery. Eur J Cardiothorac Surg (2005) 1.44
Elective versus deferred stenting following subintimal recanalization of coronary chronic total occlusions. Catheter Cardiovasc Interv (2014) 1.44
Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel. Catheter Cardiovasc Interv (2010) 1.41
Contemporary issues on clopidogrel therapy. Intern Emerg Med (2009) 1.39
Long-term clinical benefit of drug-eluting stents over bare-metal stents in diabetic patients with de novo left main coronary artery disease: results from a real-world multicenter registry. Catheter Cardiovasc Interv (2009) 1.39
First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation (2002) 1.14
Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol (2007) 1.10
RenalGuard System for the prevention of acute kidney injury in patients undergoing transcatheter aortic valve implantation. EuroIntervention (2016) 1.06
Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents. Am J Cardiol (2009) 1.04
Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J (2009) 1.02
Giant left ventricular pseudoaneurysm complicating an acute myocardial infarction in patient with previous cardiac surgery: a case report. J Cardiovasc Med (Hagerstown) (2009) 1.02
PED is overexpressed and mediates TRAIL resistance in human non-small cell lung cancer. J Cell Mol Med (2008) 0.99
Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol (2007) 0.97
Meta-analysis comparison (nine trials) of outcomes with drug-eluting stents versus bare metal stents in patients with diabetes mellitus. Am J Cardiol (2008) 0.95
Virulent strains of Helicobacter pylori and vascular diseases: a meta-analysis. Am Heart J (2006) 0.93
Comparison of drug-eluting stents and bare-metal stents for the treatment of unprotected left main coronary artery disease in acute coronary syndromes. Am J Cardiol (2008) 0.92
Assessment of the 9p21.3 locus in severity of coronary artery disease in the presence and absence of type 2 diabetes. BMC Med Genet (2013) 0.90
Cardiorenal syndrome type 3: pathophysiologic and epidemiologic considerations. Contrib Nephrol (2013) 0.90
Multicentre experience with MGuard net protective stent in ST-elevation myocardial infarction: safety, feasibility, and impact on myocardial reperfusion. Catheter Cardiovasc Interv (2010) 0.89
Pressure distension stimulates the expression of endothelial adhesion molecules in the human saphenous vein graft. Ann Thorac Surg (2003) 0.88
Validation of predictors of intraprocedural stent thrombosis in the drug-eluting stent era. Am J Cardiol (2005) 0.88
Identifying factors that predict the choice and success rate of radial artery catheterisation in contemporary real world cardiology practice: a sub-analysis of the PREVAIL study data. EuroIntervention (2010) 0.88
Prognostic role of preprocedural glucose levels on short- and long-term outcome in patients undergoing percutaneous coronary revascularization. Catheter Cardiovasc Interv (2011) 0.87
Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation: immediate and mid-term results. J Am Coll Cardiol (2004) 0.86
Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry. J Invasive Cardiol (2014) 0.86
Comparison of diamond-like carbon-coated stents versus uncoated stainless steel stents in coronary artery disease. Am J Cardiol (2004) 0.86
Early interleukin-1 receptor antagonist elevation in patients with acute myocardial infarction. J Am Coll Cardiol (2004) 0.86
Strategies of clopidogrel load and atorvastatin reload to prevent ischemic cerebral events in patients undergoing protected carotid stenting. Results of the randomized ARMYDA-9 CAROTID (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting) study. J Am Coll Cardiol (2013) 0.86
Dissecting intramyocardial hematoma masquerading as a pseudoaneurysm of left ventricular free wall: an unusual case of myocardial rupture. Catheter Cardiovasc Interv (2006) 0.86
Two-year clinical outcome with drug-eluting stents versus bare-metal stents in a real-world registry of unprotected left main coronary artery stenosis from the Italian Society of Invasive Cardiology. Am J Cardiol (2008) 0.85
High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. JACC Cardiovasc Interv (2010) 0.85
Regional thrombolytic therapy and stent implantation in an acutely occluded aortobifemoral bypass graft. J Endovasc Ther (2003) 0.84
Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention. Am J Cardiol (2009) 0.84
A meta-analysis of specifically designed randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease. Am Heart J (2011) 0.84
Appraising the impact of left ventricular ejection fraction on outcomes of percutaneous drug-eluting stenting for unprotected left main disease: insights from a multicenter registry of 975 patients. Clin Res Cardiol (2010) 0.83
Effect of dexamethasone-eluting stents on systemic inflammatory response in patients with unstable angina pectoris or recent myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol (2005) 0.83
Clinical and angiographic outcome after sirolimus-eluting stent implantation in aorto-ostial lesions. J Am Coll Cardiol (2004) 0.82
Dual chamber pacing in hypertrophic cardiomyopathy: long-term effects on diastolic function. Pacing Clin Electrophysiol (2002) 0.82
Interleukin-1 receptor antagonist levels correlate with extent of myocardial loss in patients with acute myocardial infarction. Clin Cardiol (2005) 0.82
Simplifying clinical risk prediction for percutaneous coronary intervention of bifurcation lesions: the case for the ACEF (age, creatinine, ejection fraction) score. EuroIntervention (2012) 0.81
Right coronary artery arising from pulmonary trunk: assessment with conventional coronary angiography and multislice computed tomography coronary angiography. J Cardiovasc Med (Hagerstown) (2009) 0.81
Early and long-term outlook of percutaneous coronary intervention for bifurcation lesions in young patients. Int J Cardiol (2012) 0.81
Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. Am J Cardiol (2010) 0.81
Statin loading for acute coronary syndromes. Curr Opin Cardiol (2010) 0.81
Sex-related differences in patients undergoing percutaneous unprotected left main stenting. EuroIntervention (2010) 0.81
Are drug-eluting stents superior to bare-metal stents in patients with unprotected non-bifurcational left main disease? Insights from a multicentre registry. Eur Heart J (2009) 0.81
Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. Am J Cardiol (2002) 0.81
Is intravascular ultrasound beneficial for percutaneous coronary intervention of bifurcation lesions? Evidence from a 4,314-patient registry. Clin Res Cardiol (2011) 0.80
Therapeutic strategies to prevent contrast-induced acute kidney injury. Curr Opin Cardiol (2013) 0.80
Simvastatin reduces platelet-endocardium adhesion in atrial fibrillation. Atherosclerosis (2007) 0.80
Incidence of bleeding and compliance on prolonged dual antiplatelet therapy (aspirin + thienopyridine) following drug-eluting stent implantation. Am J Cardiol (2008) 0.80
Scientific foundation and possible implications for practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site andSystemic Implementation of AngioX (MATRIX) trial. J Cardiovasc Transl Res (2014) 0.80
Comparison of clinical and angiographic outcome of sirolimus-eluting stent implantation versus cutting balloon angioplasty for coronary in-stent restenosis. Am J Cardiol (2004) 0.79
The CID Chrono cobalt-chromium alloy carbofilm-coated coronary stent system. Int J Cardiol (2010) 0.79
Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis. Am J Cardiol (2006) 0.79
Steroid-eluting stents in patients with acute coronary syndrome: the dexamethasone eluting stent Italian registry. Heart (2006) 0.79
Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv (2010) 0.78
Impact of acute coronary syndromes on two-year clinical outcomes in patients with unprotected left main coronary artery stenosis treated with drug-eluting stents. Am J Cardiol (2010) 0.78
Hand-held echocardiography in the setting of pre-operative cardiac evaluation of patients undergoing non-cardiac surgery: results from a randomized pilot study. Int J Cardiovasc Imaging (2015) 0.78
Simultaneous hybrid revascularization by bilateral carotid stenting and coronary artery bypass grafting. Catheter Cardiovasc Interv (2013) 0.78
Temporal pattern of ischemic events in relation to dual antiplatelet therapy in patients with unprotected left main coronary artery stenosis undergoing percutaneous coronary intervention. J Am Coll Cardiol (2009) 0.78
Antiplatelet therapy in patients with diabetes mellitus and acute coronary syndrome. Circ J (2013) 0.78